U S Wealth Group LLC. Invests $2.11 Million in Pfizer Inc. (NYSE:PFE)

U S Wealth Group LLC. purchased a new position in Pfizer Inc. (NYSE:PFE) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 79,636 shares of the biopharmaceutical company’s stock, valued at approximately $2,113,000. Pfizer accounts for about 1.6% of U S Wealth Group LLC.’s investment portfolio, making the stock its 28th largest position.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. United Bank grew its position in shares of Pfizer by 3.7% in the 3rd quarter. United Bank now owns 35,599 shares of the biopharmaceutical company’s stock worth $1,030,000 after buying an additional 1,277 shares during the last quarter. Janus Henderson Group PLC lifted its position in shares of Pfizer by 0.5% in the 3rd quarter. Janus Henderson Group PLC now owns 530,429 shares of the biopharmaceutical company’s stock worth $15,348,000 after purchasing an additional 2,600 shares during the period. Kovitz Investment Group Partners LLC increased its position in shares of Pfizer by 35.4% during the third quarter. Kovitz Investment Group Partners LLC now owns 366,690 shares of the biopharmaceutical company’s stock valued at $10,612,000 after buying an additional 95,896 shares during the period. DF Dent & Co. Inc. lifted its holdings in Pfizer by 11.9% in the third quarter. DF Dent & Co. Inc. now owns 45,708 shares of the biopharmaceutical company’s stock worth $1,323,000 after buying an additional 4,852 shares during the period. Finally, Dunhill Financial LLC grew its holdings in shares of Pfizer by 8,848.4% during the 3rd quarter. Dunhill Financial LLC now owns 105,323 shares of the biopharmaceutical company’s stock worth $3,048,000 after acquiring an additional 104,146 shares during the period. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Down 5.4 %

Shares of NYSE PFE opened at $22.99 on Monday. The stock’s fifty day simple moving average is $25.87 and its two-hundred day simple moving average is $26.72. Pfizer Inc. has a 12-month low of $22.28 and a 12-month high of $31.54. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The stock has a market capitalization of $130.39 billion, a PE ratio of 16.31, a price-to-earnings-growth ratio of 0.64 and a beta of 0.67.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. The firm had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company’s quarterly revenue was up 24.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.10 EPS. As a group, analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Insider Transactions at Pfizer

In other Pfizer news, Director Ronald E. Blaylock acquired 19,457 shares of the firm’s stock in a transaction on Thursday, February 13th. The stock was acquired at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the purchase, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. The trade was a 235.84 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.06% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the stock. Guggenheim reiterated a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. Truist Financial reduced their price objective on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. Citigroup reissued a “neutral” rating on shares of Pfizer in a report on Thursday, March 27th. Finally, Bank of America restated a “neutral” rating and set a $29.00 price target on shares of Pfizer in a research note on Tuesday, December 10th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, six have assigned a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.